• McKesson is expected to report a 15.9% increase in EPS to $9.31 and a 10.8% rise in revenue to $105.54 billion.
• The consensus EPS estimate has remained unchanged over the past 30 days, indicating strong analyst confidence.
• Key financial metrics reveal a P/E ratio of 26.03, a negative debt-to-equity ratio of -5.63, and a current ratio of 0.88, highlighting potential areas for investor analysis.

McKesson Corporation (NYSE:MCK) is a leading healthcare services and information technology company. It provides pharmaceuticals and medical supplies to pharmacies, hospitals, and other healthcare facilities. As a major player in the healthcare sector, McKesson competes with companies like Cardinal Health and AmerisourceBergen. The company is set to release its quarterly earnings on February 4, 2026.

Analysts expect McKesson to report earnings per share (EPS) of $9.31, a 15.9% increase from the previous year. This growth reflects the company's strong performance and market position. The revenue is projected to reach $105.54 billion, marking a 10.8% rise from the same quarter last year. These figures highlight McKesson's ability to expand its business and increase its market share.

The consensus EPS estimate has remained unchanged over the past 30 days, indicating analysts' confidence in their projections. Revisions to earnings estimates can significantly impact investor behavior, as highlighted by empirical research. A stable estimate suggests that analysts believe McKesson will meet or exceed expectations, which could positively influence the stock's short-term price performance.

McKesson's financial metrics provide further insight into its valuation and performance. The price-to-earnings (P/E) ratio of 26.03 suggests that investors are willing to pay a premium for the company's earnings. The price-to-sales ratio of 0.27 and enterprise value to sales ratio of 0.29 indicate a reasonable valuation relative to sales. The enterprise value to operating cash flow ratio of 16.16 shows the company's cash flow generation capabilities.

The company's earnings yield of 3.84% offers a perspective on the return on investment. However, the negative debt-to-equity ratio of -5.63 indicates a unique capital structure, which may warrant further analysis. Additionally, the current ratio of 0.88 suggests potential liquidity considerations, as it is below the ideal level of 1.0. These financial metrics provide a comprehensive view of McKesson's financial health and market position.